GURUFOCUS.COM » STOCK LIST » USA » NAS » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » Current Ratio
Switch to:

Intercept Pharmaceuticals (NAS:ICPT) Current Ratio

: 2.37 (As of Mar. 2023)
View and export this data going back to 2012. Start your Free Trial

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Intercept Pharmaceuticals's current ratio for the quarter that ended in Mar. 2023 was 2.37.

Intercept Pharmaceuticals has a current ratio of 2.37. It generally indicates good short-term financial strength.

The historical rank and industry rank for Intercept Pharmaceuticals's Current Ratio or its related term are showing as below:

ICPT' s Current Ratio Range Over the Past 10 Years
Min: 0.48   Med: 5.79   Max: 31.15
Current: 2.37

During the past 13 years, Intercept Pharmaceuticals's highest Current Ratio was 31.15. The lowest was 0.48. And the median was 5.79.

ICPT's Current Ratio is ranked worse than
67.24% of 1581 companies
in the Biotechnology industry
Industry Median: 4.19 vs ICPT: 2.37

Intercept Pharmaceuticals Current Ratio Historical Data

The historical data trend for Intercept Pharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.22 4.45 3.05 3.02 2.35

Intercept Pharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Current Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.16 3.22 2.46 2.35 2.37

Competitive Comparison

For the Biotechnology subindustry, Intercept Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Intercept Pharmaceuticals Current Ratio Distribution

For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Intercept Pharmaceuticals's Current Ratio falls in comparison to its industry or sector. The grey bar indicates the Current Ratio's extreme value range as defined by GuruFocus.



Intercept Pharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Intercept Pharmaceuticals's Current Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Current Ratio (A: Dec. 2022 )=Total Current Assets (A: Dec. 2022 )/Total Current Liabilities (A: Dec. 2022 )
=540.127/230.077
=2.35

Intercept Pharmaceuticals's Current Ratio for the quarter that ended in Mar. 2023 is calculated as

Current Ratio (Q: Mar. 2023 )=Total Current Assets (Q: Mar. 2023 )/Total Current Liabilities (Q: Mar. 2023 )
=490.457/207.117
=2.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intercept Pharmaceuticals  (NAS:ICPT) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Intercept Pharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Intercept Pharmaceuticals (NAS:ICPT) Business Description

Intercept Pharmaceuticals logo
Traded in Other Exchanges
Address
10 Hudson Yards, 37th Floor, New York, NY, USA, 10001
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Executives
Andrew Saik officer: EVP & Chief Financial Officer 640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey officer: President, R&D and CMO 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia officer: Chief Accounting Officer C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Lisa Defrancesco officer: SVP, IR & Corp. Affairs C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson officer: EVP & Chief Commercial Officer 2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg officer: General Counsel and Secretary 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball officer: Chief Quality Officer 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paolo Fundaro director, 10 percent owner C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener director 900 FIFTH AVENUE, #8C, NEW YORK NY 10021
Luca Benatti director C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Daniel G Welch director 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Daniel Bradbury director BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Nancy Miller-rich director C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451

Intercept Pharmaceuticals (NAS:ICPT) Headlines

Other Sources